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Angiotensin II-derived constrained 
peptides with antiplasmodial 
activity and suppressed 
vasoconstriction
Adriana Farias Silva1, Marcelo Der Torossian Torres1,2,3,4,5,6, Leandro Souza Silva7, Flavio Lopes 
Alves8, Ana Acácia de Sá Pinheiro7, Antonio Miranda8, Margareth Lara Capurro  9, Cesar de la 
Fuente-Nunez2,3,4,5,6 & Vani Xavier Oliveira Jr  1
Angiotensin II (Ang II) is a natural mammalian hormone that has been described to exhibit 
antiplasmodial activity therefore constituting a promising alternative for the treatment of malaria. 
Despite its promise, the development of Ang II as an antimalarial is limited by its potent induction of 
vasoconstriction and its rapid degradation within minutes. Here, we used peptide design to perform 
targeted chemical modifications to Ang II to generate conformationally restricted (disulfide-crosslinked) 
peptide derivatives with suppressed vasoconstrictor activity and increased stability. Designed 
constrained peptides were synthesized chemically and then tested for antiplasmodial activity. Two lead 
constrained peptides were identified (i.e., peptides 1 and 2), each composed of 10 amino acid residues. 
These peptides exhibited very promising activity in both our Plasmodium gallinaceum (>80%) and 
Plasmodium falciparum (>40%) models, an activity that was equivalent to that of Ang II, and led to 
complete suppression of vasoconstriction. In addition, peptide 5 exhibited selective activity towards 
the pre-erythrocytic stage (98% of activity against P. gallinaceum), thus suggesting that it may be 
possible to design peptides that target specific stages of the malaria life cycle. The Ang II derived stable 
scaffolds presented here may provide the basis for development of a new generation of peptide-based 
drugs for the treatment of malaria.
Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic protozoa 
from the genus Plasmodium. Five hundred thousand people die annually from malaria, mostly children under 
the age of five, with 90% of cases occurring in Sub-Saharan Africa1,2. In addition, an estimated 250 million people 
suffer from malaria each year1,2.
Angiotensin II (Ang II) is an octapeptide hormone that plays a central role in cardiovascular homeostasis, 
acting as a vasoactive agonist that induces contraction of blood vessels. Ang II raises blood pressure via vasocon-
striction, sympathetic nervous stimulation, and increased aldosterone biosynthesis and renal actions. This pep-
tide has been shown to exhibit antiplasmodial activity3–8, thus representing a promising novel anti-malaria drug. 
However, Ang II is limited by its rapid degradation (i.e., short half-life)9, and its potent vasoconstrictor effect10.
Recent efforts have focused on modifying the primary structure of Ang II to generate synthetic variants with 
conserved antiplasmodial activity but suppressed vasoconstrictor effect3–8. For example, Maciel et al., synthesized 
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six Ang II analogs, three linear and three restricted peptides, designed via introduction of two amino acid resi-
dues (D and K) to the N-terminus. This resulted in the formation of a lactam bridge with a scaffold that increased 
the potency of the peptide towards parasite lipid membranes4,11. In the same study, linear VC-4 (DDRKVYIHPF) 
and restricted VC-5 (DRDVKYIHPF) peptides presented biological activity (64% and 78%, respectively), but only 
VC-5 displayed complete depletion of vasoconstrictor effects4.
In constrained peptides, the insertion of a lactam bridge at the Ang II N-terminus increased the antiplasmo-
dial activity when compared to peptides that contain the lactam ring within the C-terminus3. To understand the 
effect of ring position, bridgehead elements and ring size of Ang II derivatives, Torres et al. further modified the 
VC-5, VC-17 and VC-19 analogs6. New peptides containing i-(i + 2); i-(i + 3) or i-(i + 4) lactam bridge scaffolds 
were synthesized with E or D and O or K amino acid residues, and D- and L-enantiomers as bridgehead elements. 
Three of these analogs (i.e., EDRKVYIHPF; EDRVOYIHPF; eDRVOYIHPF) maintained the antiplasmodial 
activity of Ang II. Almost all the designed peptides tended to adopt a β-turn conformation, in agreement with 
the conformational tendency of the native molecule, except for eDRVOYIHPF, which tended to adopt an α-helix 
conformation in the studied solvents6.
Silva et al.12, tested several linear Ang II derivative peptides in vitro using both the P. gallinaceum sporozoite 
and the P. falciparum blood stage models. Two short peptides presented high antiplasmodial activity: YHPF and 
VIPF presented 89% and 94% activity against P. gallinaceum, respectively, and ~50% activity against erythrocyte 
invasion by P. falciparum. These derivatives exhibited an activity that was equipotent to that of Ang II against 
Plasmodium sporozoites and repressed pressor activity.
The small linear peptides12 and the constrained derivatives previously described7,8 were used here as templates 
for the design of a new class of stable13 constrained peptides that retain higher antiplasmodial (~98% inhibi-
tion) activity cf. Ang II (~88% inhibition). These constrained peptides suppressed vasoconstriction effects similar 
to previously described Ang II analogs. Our findings present novel peptides with selective activity against the 
pre-erythrocytic cycle of malaria and represent promising templates for the prevention of malaria.
Results
Peptide design, synthesis and characterization. All peptides were designed, synthesized and evaluated 
for their potential as novel antiplasmodial drugs. These analogs were purified and characterized as described in 
the Methods Section, resulting in a chromatographic purity >96% in all cases. Mass characterization by LC/
MS-ESI (+) confirmed the chemical identity of peptides and was in agreement with the expected molecular 
weight theoretical values (Table 1).
Circular Dichroism (CD). We then performed CD spectra experiments to determine the secondary structure 
of the peptides. The results obtained indicate that all peptides were unfolded and tended to adopt a random-coil 
conformation, except for peptides 6 and 7 that tended to form a β-turn14 structure in SDS solvent (Fig. 1).
Effect of peptides against Plasmodium gallinaceum sporozoites during the pre-erythrocytic 
cycle of malaria. The effect of the peptides on sporozoites was determined in vitro by fluorescence micros-
copy. Briefly, the parasites were incubated for one hour in the presence of each peptide and the fluorophore 
propidium iodide, which stains dead and dying cells. The results are reported as the percent of fluorescent (i.e., 
inactivated) sporozoites. The analyses were carried out in triplicate, using three different mosquito batches 
(n = 9). The in vitro effect of peptides on P. gallinaceum sporozoites using our assay showed activity up to 98%, 
equipotent to the positive control digitonin, a surfactant that triggers uptake of propidium iodide into damaged/
dead cells (Fig. 2A).
Effect of peptides in the erythrocytic cycle of Plasmodium falciparum. The effect of peptides in the 
P. falciparum erythrocytic cycle was assayed in vitro against a synchronized culture in the schizont form of P. falci-
parum, maintaining 5% hematocrit and 2% parasitemia. Twenty-four hours after treatment, all peptides reduced 
new ring formation within erythrocytes at 10−8 mol L−1, which was described by Saraiva et al. as the ideal con-
centration for these inhibition assays15. The tests were carried out in duplicate and a total of ten experiments were 
performed (n = 10). Data were normalized due to differences between controls from each assay. It was observed 
that three analogs reduced the number of rings formed in the blood stage, but only analogs 1 and 2 presented 
inhibition >40%, when compared to the untreated controls (Fig. 2B).
The IC50 value represents the peptide concentration leading to a 50% reduction in the number of P. falciparum 
rings formed, when compared to untreated control cultures. The IC50 assays were performed using lead analogs 
1 and 2, which presented >40% inhibition of ring form formation (Fig. 2C and D). Seven concentrations were 
tested with inhibitory activities that ranged from 8.5–54.5%.
Hemolytic effect of peptides. Assessing toxicity is a key requirement for translating novel compounds 
into the clinic. Therefore, we evaluated the hemolytic activity of Ang II peptide derivatives 1 and 2 towards eryth-
rocyte human cells. Erythrocytes were seeded in 96-well plates in the absence (negative control) or presence of 
10−8 mol L−1 of the analogs, as described in the Methods Section. The peptides did not present hemolytic effects 
(Fig. 3).
Contractile response of peptides. Since one of the main limitations of Ang II as an antiplasmodial agent 
is its ability to increase blood pressure, here we tested the contractile response induced by our designer peptide 
analogs. These assays revealed that all peptides tested were inactive when compared to positive controls Ang II 
and carbachol (Fig. 4), therefore confirming the potential of lead peptides 1 and 2 as novel antimalarial therapies.
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Stability of peptides. A major concern for the translation of peptides into the clinic is their limited stability. 
Here we tested the resistance of our designer Ang II derivatives to degradation in human serum. These assays 
revealed that most of the constrained peptides tested were resistant to degradation in human serum (Fig. 5) 
even after a long time of exposure (6 hours). Therefore, these results confirm the expected increased stability of 
constrained peptides, and further highlight the antimalarial potential of lead peptides 1 and 2, which exhibited 
excellent stability in these assays.
Discussion
As noted in previous work7,8,16–18, design of constrained peptides via S-S bonds contributes to the activity of 
peptides against P. gallinaceum sporozoites and leads to moderate activity (20–30%) against P. falciparum in the 
erythrocytic stage. This work presents the design of constrained peptides derived from the primary sequence of 
Ang II, which exhibit higher antiplasmodial activity than Ang II in two separate parasite models. Some of the 
designed peptides have a size advantage over their predecessors (~10 residues), as they are smaller (8 residues 
for peptide CRYHIPFC, which exhibited 98% antiplasmodial activity) and therefore more cost effective to man-
ufacture as potential therapies. All of the constrained peptides presented high resistance to degradation in the 
Entry Sequence
HPLC 
puritya 
(%)
Calculed 
massb (g 
mol−1)
Observed 
massb (g 
mol−1)
Antiplasmodial 
activity vs P. 
gallinaceum 
(% fluorescent 
sporozoites)
Antiplasmodial 
activity vs P. 
falciparum (new 
ring formation%) Design rationale
Ang II DRVYIHPF 88 47 WT peptide
1 CDRVYIHPFC 98 1249.6 1250 92 42 Constrained version of Ang II.
2 CDRVYHIPFC 98 1249.6 1250 91 42
Residues H and I were 
reversed, which is 
expected to increase 
antiplasmodial activity 
based on previously 
described linear variant12
3 CDRVCYHIPF 98 1249.6 1250 82 11
Designed based on most 
potent antiplasmodial 
peptide (CDRVCYIHPF) 
obtained previously16, 
with an additional IH 
reverse modification.
4 CDRVYPFC 97 999.4 1000 95 9
Hydrophobic patch 
composed of H and I 
was deleted to assess its 
influence on function.
5 CRYHIPFC 98 1035.5 1036 98 0
D and V were deleted 
to optimize interactions 
between R and Y within 
the same plane. I and H 
were reversed to evaluate 
the effect of new pi-stack 
interactions in the 
activity.
6 CRYPFC 99 785.3 786 4 29
Most important residues 
for function within 
the Ang II sequence 
were kept to build a 
minimal peptide with 
antiplasmodial activity.
7 CYHPFC 97 766.3 767 6 17
Only aromatic residues 
were kept inspired by 
the linear form (YHPF), 
which was one of our 
lead peptides previously 
described12.
8 CVIPFC 98 675.3 676 7 3.5
Aliphatic and 
hydrophobic residue 
F were kept, based on 
previous lead linear 
peptide (VIPF)12.
Table 1. Design of angiotensin II-derived synthetic peptides. Purity of peptides determined by LC/MS is 
shown, along with their respective antiplasmodial activity and design rationale. aHPLC profiles were obtained 
under the following conditions: Column Supelcosil C18 (4.6 × 150 mm), 60 Å, 5 μm; Solvent System: A (0.1% 
TFA/H2O) and B (0.1% TFA in 60% ACN/H2O); Gradient: 5–95% B in 30 min; Flow: 1.0 mL/min; λ = 220 nm; 
Injection Volume: 50 μL and sample concentration: 1.0 mg/mL. bThe masses were determined by LC/ESI–
MS using a Micromass instrument (model ZMD) coupled to a Waters Alliance (model 2690) system. Mass 
measurements were performed in a positive mode with the following parameters: mass range between 300 and 
2000 m/z; nitrogen gas flow: 4.1 L/h; capillary: 2.3 kV; cone voltage: 32 V; extractor: 8 V; source heater: 100 °C; 
solvent heater: 400 °C; ion energy: 1.0 V and multiplier: 800 V.
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presence of human serum proteases, except for the partially restricted analog 3 (Fig. 5), which presents exposed 
basic residues (i.e., preferential cleaving site for endopeptidases), and peptide 5 (Fig. 5), which has a positive 
charged group next to its N-terminus that likely exposes the Arg guanidinium group to proteases.
Manning et al. showed that even small peptide backbone conformational distortions can cause pronounced 
changes in CD signals, therefore demonstrating the suitability of CD to monitor conformational changes with 
high sensitivity19. Here, we used CD to: (A) verify the conformational tendency of constrained peptides cf. lin-
ear peptides12 and (B) propose a model for peptide-membrane interactions based on the conformational ten-
dency adopted when peptides are restricted with disulfide bonds by using SDS micelles to mimic a biomembrane 
environment. Our findings revealed that (A): linear peptides12 adopted different β-turn conformations and 
restricted peptides tended to form random coil structures, except for peptides 6 and 7, which adopted β-turn 
conformations in SDS solvent (Figure 1)14. (B): peptides 1–5 and 8 tended to adopt random coiled conforma-
tions in SDS medium, a different behavior when compared to their linear analogs, which tended to adopt β-turn 
conformations.
Peptides were separated into three functional groups based on results obtained in the biological activity assays 
against P. gallinaceum sporozoites (Fig. 2A): group 1 – active peptides: with antiplasmodial activity >90%, which 
includes peptides 1, 2, 4 and 5; group 2 – peptide with moderate antiplasmodial activity (~82%), comprising 
peptide 3 (data is statistically significant compared with groups 1 and 3); and group 3 – non-active peptides: 
exhibiting antiplasmodial activity <15%, include peptides 6, 7 and 8.
Peptides 1 and 2 differ in residues Ile5 and His6. Analog 4 was designed via the removal of these two residues. 
Silva et al., studied linear peptides and observed that peptide DRVYHIPF had potent biological activity (94% 
against P. gallinaceum sporozoites). The sequence of peptide 1 is similar to that of Ang II, whereas peptide 2 
presents a sequence that resembles Ang II with modifications in His and Ile residues (DRVYHIPF). Peptide 
4, on the other hand, lacks Ile and His amino acid residues within its backbone. Furthermore, all peptides are 
restricted with a S-S bond, obtained through the insertion of two Cys residues in their extremities (both Nt and 
Ct). These results suggest that, for peptides 1, 2 and 4, the incorporation of S-S bonds did not interfere with the 
parasite-peptide interaction (i.e., antiplasmodial activity) when compared with Ang II or the linear counterpart 
of peptide 2, studied by Silva et al.12. We hypothesize that this may be due to the fact that restriction tends to pro-
mote rigidity on the molecule, therefore inducing intramolecular interactions between the peptide side chains 
Figure 1. Circular dichroism spectra of constrained peptides. Spectra were recorded after four accumulations 
at 20 °C using a 0.5 mm path-length quartz cell between 260 nm and 195 nm at 50 nm/min with a band width of 
0.5 nm. All peptides were analyzed in the following four solutions: 15 mM PBS, 10 mM SDS/PBS, 50% TFE/PBS, 
and 50% MeOH/PBS. The peptide concentration was approximately 10−4 mol L−1.
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Figure 2. Antiplasmodial activity of designed synthetic peptides. (A) Effect of peptides on sporozoite 
membrane permeability expressed as % fluorescent mature sporozoites (mean ± standard deviation, n = 9). 
Letters indicate those results not significantly different from each other at p < 0.05 level. Positive control 
group (+): digitonin/PBS; negative control group (−): PBS. The most active peptides were 1, 2, 4 and 5 
that presented 92, 91, 95 and 98% antiplasmodial activity, respectively. (B) Effect of peptides in new ring 
formation. The percentage of rings was determined after 24 h incubation of erythrocyte cultures infected with 
2–3% schizonts in the absence (control) or presence of 10−8 mol L−1 of peptides. Double asterisk statistically 
significant compared with control value p < 0.01. Triple asterisk statistically significant compared with 
control value p < 0.001. Dark grey shading indicates that the result is statistically significant compared with 
control (mean ± standard deviation, n = 2). Data corresponding to ring form % in the presence of Ang II 
was retrieved from Saraiva et al.15. Ring formation inhibition (IC50 values) mediated by designed peptides 1 
(C) and 2 (D). Peptides were diluted to seven concentrations [(10−4; 10−6; 10−8; 10−9; 10−10; 10−12; 10−14) mol 
L−1] leading to an inhibitory range between 6–54.5%. Data have been normalized due to differences between 
controls of each assay. The IC50 data were analyzed by GraphPad Prism analysis. Parameters: non-linear 
regression; log (inhibitor) vs response equation was chosen and least square (ordinary) fit method was applied 
(mean ± standard deviation, n = 2).
Figure 3. Hemolytic assay of human red blood cells. Red blood cells were treated with distilled water which 
causes lysis of red blood cells; uninfected erythrocytes were kept in the same conditions used in the invasion 
assay with a control and each peptide tested (10−8 mol L−1), at 37 °C for 24 h. After incubation, the supernatant 
was collected, clarified at 900 g/8 min and the hemoglobin content was detected in a spectrophotometer at 
530 nm. **** denotes statistical significance of group compared with distilled water value p < 0.05. Light 
grey shading indicates that the result is not statistically significant compared with control (mean ± standard 
deviation, n = 3).
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and the potential for hydrogen bond formation with adjacent amino acids. In addition, disulfide bonds can lock 
peptide structure into its bioactive conformation, thereby enhancing selectivity and potency17.
Mutating Ile and His residues in peptide 5 to generate peptide 6 led to a substantial decrease in antiplasmodial 
activity: peptide 5 presented 98% antiplasmodial activity whereas peptide 6 showed 4% (Fig. 2). Depletion of 
antiplasmodial function upon mutation of Ile and His may be explained by: a) the presence of a disulfide bridge, 
which may lead to cation-π interactions between Tyr-His side chains, with possible hydrogen bonding12 b) inter-
actions between residues that play an important role in the biological activity as the hydrophobic cluster formed 
by Tyr-His-Ile on hairpin structure of native Ang II, studied by Tzakos et al.20 c) the amount of amino acid resi-
dues, given that large S-S rings generally have higher biological activity17, and also observed in peptides 7 and 8.
Torres et al.7 studied Ang II analogs with S-S bonds and showed that restricted peptides presented antiplas-
modial activity. Peptide sequence CDRVCYIHPF7 presented 76% (±3) antiplasmodial activity vs sporozoites of 
P. gallinaceum. Silva et al., studied different linear Ang II derivative peptides12 and observed that when His and 
Ile residues are inverted, the antiplasmodial activity increased cf. peptides with the native primary sequence. To 
verify this observation, here we inverted the position of Ile and His residues in peptide 3. The resulting peptide 
presented increased antiplasmodial activity [82% (±1)] compared to its analogs7.
Previous studies showed that Ang II and its analogs presented antiplasmodial activity in the erythrocytic stage 
as observed by Saraiva et al., using a P. falciparum erythrocytic cycle in vitro model15. The authors observed that 
Ang II reduced by 47% reinfection caused by ring forms. Silva and colleagues tested linear Ang II derivatives 
using the same model and observed that two short peptides were capable of reducing parasite reinfection >50%12. 
In this work, we tested designer peptides using the P. falciparum erythrocytic cycle and observed that two pep-
tides (1 and 2) were able to reduce parasite reinfection >40% (Fig. 2B). Generally, larger restricted peptides 
(>5,000 Da) were more active than shorter (<500 Da) restricted peptides13. This is not entirely surprising as small 
peptide molecules are known to exhibit low target specificity which may interfere with their biological function17.
Only peptides 1 and 2 presented antiplasmodial activity in both models in addition to exhibiting resistance 
to degradation by human serum proteases (Fig. 5), thus subsequent studies focused on these two lead variants. 
The IC50 values of these peptides were determined in vitro (Fig. 2C,D) by testing seven concentrations resulting 
in 8.5–54.5% inhibition when using 1.10 × 10−9 mol L−1 of peptide 1 and 1.81 × 10−9 mol L−1 of peptide 2. Saraiva 
observed that Ang II at 10−8 mol L−1 of exerted its maximum effect at inhibiting parasite reinfection, as it reduced 
merozoite reinvasion by 47%15. To verify if peptides 1 and 2 had the same effect as Ang II, they were tested at 10−8 
mol L−1 and led to parasitemia reductions of 42.5% for both peptides (Fig. 2B). The results showed that peptides 1 
Figure 4. Effect of Ang II derived peptides in contractile responses by muscle tissue incubation compared 
to carbachol (CCh) activity. Triple asterisk statistically significant compared with control value p < 0.05 
(mean ± standard deviation, n = 2).
Figure 5. Stability of Ang II derivatives in human serum. Aliquots of peptides in the presence of human serum 
were taken over time (from 0 to 6 h) and were analyzed by LC-MS/ESI. The values shown correspond to % of 
area under the peak normalized according to the initial concentration of each peptide. All experiments were 
performed in duplicate.
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and 2 were able to reduce parasite reinfection to levels similar to Ang II15. In addition, we found that lead peptides 
1 and 2 lacked hemolytic activity, as they induced <6% hemolysis of red blood cells (Fig. 3). Importantly, none of 
the peptides led to a significant contractile response (Fig. 4), which is an important limitation of Ang II.
Overall, we have designed novel restricted peptides that are mostly resistant to degradation by proteases and 
that exhibit potent antiplasmodial activity in vitro against Plasmodium gallinaceum sporozoites. Four peptides 
presented >90% activity against Plasmodium. Two of them presented inhibitory activity that was comparable to 
that of the positive control digitonin, which promotes 100% lysis of parasite membranes. Peptides 4 and 5 consti-
tute promising candidates for the treatment of malaria in its pre-erythrocytic stage. Restricted peptides presented 
potential antiplasmodial activity in vitro against erythrocyte invasion by Plasmodium falciparum. Peptides 1, 
2 and 6 were able to reduce reinfection by the parasite, whereas peptides 1 and 2 presented equipotent activity 
in both models and were equipotent to Ang II. Peptides 1 and 2 are promising pre-erythrocytic and erythro-
cytic drug candidates that show potential in the prevention of malaria. On the other hand, peptide 6 was the 
only one that presented activity exclusively against erythrocyte invasion by P. falciparum. Although its biolog-
ical activity was not equipotent to Ang II, the selectivity demonstrated by this peptide makes it an interesting 
template sequence for the design of peptides that selectively target specific stages of the Plasmodium life cycle. 
Vasoconstriction suppression was achieved in all cases as none of the peptides led to contractile responses and 
the restriction design strategy proved to lead to resistance to degradation by proteases for most peptides, except 
for the ones that presented basic residues exposed (Fig. 5), thus reinforcing the promise of these molecules as 
novel drugs.
In the sporozoitic stage of the P. gallinaceum cycle (Fig. 2A), our peptides may interact with P. gallinaceum cells 
by binding and destabilizing the membrane of P. gallinaceum sporozoites, as previously reported (Maciel et al., 
PLoS One, 2008). On the other hand, in the merozoitic stage of the P. falciparum cycle (Fig. 2B), our peptides may 
operate via a distinct mechanism, which is currently under investigation.
In conclusion, we present novel stable and nontoxic Ang II synthetic stable peptide derivatives with antiplas-
modial function that represent promising agents for the prevention and treatment of malaria.
Methods
Peptide Synthesis. Peptides were synthesized by manual solid-phase synthesis; we leveraged 9-fluoren-
ylmethyloxycarbonyl (Fmoc)21 using Wang22 resin (aapptech, USA) with ~0.5 mmol g−1 substitution degree. A 
treatment with 20% 4-methylpiperidine (4-MePip) in dimethylformamide (DMF) for 40 min was applied to 
unprotect Fmoc-Amino acids (NovaBiochem) residues. Couplings were carried out using 2,5-fold molar excess 
of the Fmoc-protected amino acid, activated by N,N′-diisopropylcarbodiimide (DIC)/Hydroxybenzotriazole 
(HOBt), for 2 hours at room temperature, in Dichloromethane (DCM)/DMF (1:1, v/v) and monitored by the 
colorimetric Kaiser test23. Each step was followed by a washing procedure with DMF, methanol and DCM to 
alternately change the degree of resin swelling, favoring the elimination of excess reagents and byproducts24.
To cleave the peptide from the resin, dry-protected peptidyl-resin was exposed to trifluoroacetic acid (TFA)/
water/anisole (95:2.5:2.5, v/v/v) for two hours at room temperature. The crude deprotected peptides were pre-
cipitated with anhydrous diethyl ether, filtered from the ether-soluble products, extracted from resin with 60% 
acetonitrile (ACN) in water and lyophilized.
The S-S bonds were formed by first solubilizing the crude peptides (1 g L−1) in an 80% acetic acid solution 
containing 0.04 mol L−1 iodine25. After 40 min, the reaction was extracted with water and diethyl ether. After that, 
the diethyl ether was evaporated, and the resulting solution was lyophilized.
The crude peptides were purified by preparative reverse-phase high-performance liquid chromatography 
(RP-HPLC) in 0.1% TFA/H2O (solvent A) and 0.1% TFA/60% ACN/H2O (solvent B) on a Delta Prep 600 (Waters 
Associates system, Milford, MA, USA). Briefly, the peptides were loaded onto a Phenomenex C18 (21.2 × 250 mm, 
15 µm particles, 300 Å pores) column at a flow rate of 10.0 mL min−1 and eluted using a linear gradient (0.33% 
solvent B/min slope) of 0.1% TFA − 60% ACN/H2O with detection at 220 nm. Selected fractions containing 
the purified peptides were pooled and lyophilized. Purified peptides were characterized by liquid chromatog-
raphy electrospray ionization mass spectrometry (LC/ESI-MS) (Table 1). LC/ESI-MS data were obtained on a 
Model ZMD mass spectrometer (Micromass, Milford, MA, USA) coupled to a Model 2690 HPLC system (Waters 
Alliance, Milford, MA, USA) using a Phenomenex Gemini C18 column (2.0 × 150 mm, 3.0 µm particles, 110 Å 
pores). Solvent A was 0.1% TFA in water, and solvent B gradient was performed over 30 min, and peptides were 
detected at 220 nm. Mass measurements were performed in a positive mode with the following conditions: mass 
range between 500 and 2000 m/z, nitrogen gas flow rate at 4.1 L h−1, capillary voltage at 2.3 kV, cone voltage at 
32 V, extractor at 400 °C, ion energy at 1.0 V and a multiplier at 800 V.
Circular Dichroism Spectroscopy. The peptides were measured in four solutions: 15 mmol L−1 PBS 
(pH = 7.4), 10 mmol L−1 SDS in PBS, 50% TFE in PBS, and 50% MeOH in PBS. The peptide concentration was 
10−4 mol L−1. (FAR-UV) CD (190–260 nm) spectra were recorded at room temperature. It was using a 0.5 mm 
path-length quartz cell in a Jasco J815 spectropolarimeter (Tokyo, Japan). Accumulations of four analyses were 
recorded for the spectra data. The scan rate was 50 nm min−1 with band width of 0.5 nm. The CD spectra for the 
SDS, TFE and MeOH solutions were subtracted, and to minimize background effects a Fourier transform filter 
(FFT) was applied.
Mosquito rearing and maintenance of the parasite life cycle. Aedes aegypti RED strain was used in 
experiments due to their hypersensitivity to P. gallinaceum parasite26. Mosquitoes were reared using standard lab-
oratory procedures27. An aliquot of frozen chicken blood infected with the P. gallinaceum strain 8 A was obtained 
from A Krettli (René Rachou Institute of Research, FIOCRUZ, MG, Brazil). This sample was used to inoculate 
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and establish initial infections in chickens. All subsequent infections of chickens and mosquitoes were accom-
plished by feeding the mosquitoes on the chickens.
Effect of peptides on salivary gland-derived Plasmodium gallinaceum sporozoites. Nine thou-
sand P. gallinaceum mature sporozoites were pulled from the salivary glands of A. aegypti and incubated in 50 μL 
of PBS solution, with 40 μmol L–1 digitonin (positive control), 60 μmol L–1 peptides or negative control (PBS solu-
tion), at 37 °C for one hour. Cell membrane integrity was then observed using a Carl Zeiss inverted fluorescence 
microscope (model Observer Axio Vision A.1) coupled to an image capture Zeiss AxioCam HR digital camera 
(1,300 × 1,030 pixels resolution and 8-bit quantization) after addition of 1 μL of the propidium iodide aqueous 
solution (200 μmol L–1) in 5 μL of total solution volume. Images were obtained using a 40X objective lens and a 
green filter effect in red. The spectral range was set with the excitation at 538 nm within the visible spectrum in 
order to produce orange-red fluorescence centered at 619 nm, which was processed using the Axio 4.7 software.
Plasmodium falciparum in vitro assay. The erythrocytic cycle of Plasmodium falciparum was main-
tained in vitro by culturing W2 strains in 1640 medium, supplemented with A-type human blood and serum, as 
described by Saraiva et al.15 The parasite first samples were donated by Dr. Mariano Zalis from the Laboratory 
of Infectology and Parasitology, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de 
Janeiro, Rio de Janeiro, Brazil.
Erythrocytic invasion assessment by Plasmodium falciparum assay. To synchronize the parasite 
cultures into the ring stage, we used a sorbitol solution (5%) according to Lambros and Vanderberg28. The resist-
ant ring forms were maintained in culture as described above. Erythrocytes infected by parasite mature forms at 
2–3% parasitemia and 5% hematocrit were kept in the presence or absence of 10−8 mol L−1 synthetic peptides, 
for 24 h. Invasion was evaluated by the appearance of new ring forms. The invasion percentage was determined 
by optical microscopy (1000x magnification), which represents the total number of cells infected by rings in 100 
erythrocytes in at least ten random microscopic fields. The invasion assay was carried out using two different cell 
suspensions and generated equivalent results.
IC50 value determination. A dose-response relationship assay was carried out for 24 h with concentrations 
ranging from 10−14 to 10−4 mol L−1 of each peptide in order to determine the IC50 values for peptides 1 and 2 for 
suppression of erythrocytic invasion by P. falciparum. The IC50 values were calculated using GraphPad Prism 
Software version 5.00 for Windows (GraphPad, San Diego, California, USA). Parameters: Nonlinear Regression; 
log (inhibitor) vs. response equation was chosen at least square (ordinary) fit method was applied.
Hemolytic effect of peptides. The hemolytic effect of analogs 1 and 2 was determined in uninfected eryth-
rocytes. Cells were maintained in the same culture conditions in the presence of 10−8 mol L−1 of peptides for 
24 h. Erythrocytes were centrifuged at 900 g for 8 min. The free hemoglobin in the supernatant was monitored 
by spectrophotometer at 550 nm. Untreated cells were used as negative control to rule out nonspecific hemolysis. 
The hemolytic activity was expressed as a percentage of the control. This positive control (100% hemolysis) was 
prepared by treating the erythrocytes with distilled water.
Contractile response assays. The bioassay experiment was carried out in duplicate and generated equiv-
alent results. Experiments were carried out using C57BL/6 J mice from the Centro de Desenvolvimento de 
Modelos Experimentais da Universidade Federal de São Paulo (CEDEME-UNIFESP).
Stomach fundus was isolated from each mouse, divided into two strips along the longitudinal muscle, and 
mounted into 5 mL organ baths containing modified Krebs-Ringer solution [144 mmol L–1 NaCl, 5 mmol L–1 KCl, 
1.1 mmol L–1 MgSO4, 25 mmol L–1 NaHCO3, 1.1 mmol L–1 NaH2PO4, 1.25 mmol L–1 CaCl2, and 5.5 mmol L–1 glu-
cose at 37 °C (pH 7.4)] and were continuously carboxygenated (95% O2/5% CO2)29. Contractile responses to the 
stimulations with Ang II and analogs 1 and 2 (10–8 mol L–1) were measured with a TRI201 tension transducer 
(PanLab) through an amplifier (Powerlab 4/30). Data were collected through Labchart Pro V7 software. The 
resting tension was maintained at 0.5 g and the tissues were left to equilibrate for 90 min. The bath solution was 
frequently changed. The maximal effect was obtained by comparing contractile responses induced by carbachol 
(10–8 mol L–1).
Stability on human serum. The Ang II derivatives resistance to degradation assay was carried out in 
human serum of healthy donors. A 20 μL aliquot of a 10 mg mL−1 peptide solution was added to 980 μL of a 25% 
fresh serum solution in water. The new solution was incubated at 37 °C and 50 μL were taken in 0, 5, 15, 30, 60, 
120, 240 and 360 min. Serum protein were precipitated by adding 5 μL of TFA and after 10 min of incubation 
the solutions were centrifuged (300 g) for 5 min. The supernatant (20 μL) was injected in a LC-MS/ESI system. 
Absorbance in 0 min was measured and the percentage of reminiscent peptide was calculated by comparing peak 
areas of the next aliquots to the concentration of the first measurement.
Statistical analysis. The experiments were performed in independent cell suspensions. The data were ana-
lyzed by one-way analysis of variance using treatments as factors. The significance of the differences was verified 
by the Bonferroni adjustment. Statistical analysis was performed using absolute values; the data are expressed 
as the mean ± standard deviation: n = 3. All of them were considered statistically significant compared with the 
control value (or water distilled in erythrocytic haemolysis assay), if p < 0.05. GraphPad Prism version 5.00 for 
Windows was used (GraphPad Software, San Diego, California, USA).
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Ethics statement. Plasmodium falciparum and erythrocyte hemolysis assays. The collection of human 
blood samples for this study was conducted according to protocol 074/10 and approved by the Research Ethics 
Committee of the Hospital Universitário Clementino Fraga Filho at the Universidade Federal do Rio de Janeiro. 
Informed consent was obtained to enable collection of human blood samples for this study.
Plasmodium gallinaceum. The collection of Gallus gallus domesticus blood samples for this study was conducted 
according to the current guidelines for the care and use of laboratory animals as well as the ethical guidelines for 
investigations, and these experiments were preapproved by the Animal Care Committee of the Universidade de 
São Paulo, number 133.
Contractile response assay. The pharmacological experiment followed the current guidelines for 
the care and use of laboratory animals as well as the ethical guidelines for investigations, and these experi-
ments were preapproved by the Animal Care Committee of the Universidade Federal de São Paulo, number 
2013/479357.
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